Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Nov 26;7:103. doi: 10.1186/s13048-014-0103-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Wang et al.; licensee BioMed Central Ltd. 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Acquired trastuzumab-resistant cell line SKOV3-T cells grow faster than SKOV3. SKOV3 cells were cultivated for 8 months in the presence of 20 μg/ml trastuzumab continuously to obtain SKOV3-T cells. The comparison of SKOV3-T and parental SKOV3 cells by (A) cell proliferation, (B) cell counting, (C) agar clone formation, (D) transwell, and (E) in vivo carcinogenic assays. In cell counting assays, cells were cultured in day 0 at the start concentration of 1 × 10⁴ per 24-well, and in day 1 to day 6, the cells were digested everyday and the whole cell number was counted. The trastuzumab-resistant SKOV3-T seemed to have significantly enhanced cell growth/proliferation, clone formation, stronger invasion and migration character both in vitro and in vivo versus non-resistant SKOV3 cells.